Celcuity Inc.

NASDAQ: CELC · Healthcare · Biotechnology

PublicHQ Minneapolis, MN · HennepinCIK 0001603454Reports USD

#1 of 1,420 Healthcare companies by revenue

EA Score

——

FH 44DQ —GM —SS 68

v0.1 · 35/100 weight · pillars only

↑ market scale, Altman-Z · ↓ return on equity, Piotroski F

Methodology →

Revenue TTM

$94.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$177.0M

Employees

155

as of 2026-08-07

Market cap

$4.5B

as of 2026-08-07

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$177.0M-$177.0M2025

Operating income-$172.2M-$172.2M2025

Total assets$466.6M$466.6M2025

Liabilities$366.0M$366.0M2025

Equity$100.6M$100.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Celcuity Inc.’s financial profile?

Celcuity Inc. earned -$177.0M in FY2025 net income.

Peers · Healthcare

Definium Therapeutics, Inc.——Dyne Therapeutics, Inc.——Edgewise Therapeutics, Inc.——Veradermics, Incorporated——Enliven Therapeutics, Inc.——Legend Biotech Corporation——

Neighbors

Hennepin →

UnitedHealth Group Incorporated$447.6B80B+U.S. Bancorp$28.7B66B Target Corporation$104.8B81B+Ameriprise Financial, Inc.$18.9B72B Xcel Energy Inc.$11.5B67B General Mills, Inc.$18.4B67B

Key facts

CEOBrian F. Sullivan

SectorHealthcare

IndustryBiotechnology

HeadquartersMinneapolis, MN

ExchangeNASDAQ: CELC

Employees155

IPO date2017-09-19

Latest filings

8-K2026-08-26 8-K2026-08-13 10-Q2026-08-13 8-K2026-07-15 8-K2026-06-08 8-K2026-06-02 8-K2026-05-18 10-Q2026-05-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.